_version_ 1784901797989580800
author Moreau, Philippe
Chari, Ajai
Oriol, Albert
Martinez-Lopez, Joaquin
Haenel, Mathias
Touzeau, Cyrille
Ailawadhi, Sikander
Besemer, Britta
de la Rubia Comos, Javier
Encinas, Cristina
Mateos, Maria-Victoria
Salwender, Hans
Rodriguez-Otero, Paula
Hulin, Cyrille
Karlin, Lionel
Sureda Balari, Anna
Bargay, Joan
Benboubker, Lotfi
Rosiñol, Laura
Tarantolo, Stefano
Terebelo, Howard
Yang, Shiyi
Wang, Jianping
Nnane, Ivo
Qi, Ming
Kosh, Michele
Delioukina, Maria
Goldschmidt, Hartmut
author_facet Moreau, Philippe
Chari, Ajai
Oriol, Albert
Martinez-Lopez, Joaquin
Haenel, Mathias
Touzeau, Cyrille
Ailawadhi, Sikander
Besemer, Britta
de la Rubia Comos, Javier
Encinas, Cristina
Mateos, Maria-Victoria
Salwender, Hans
Rodriguez-Otero, Paula
Hulin, Cyrille
Karlin, Lionel
Sureda Balari, Anna
Bargay, Joan
Benboubker, Lotfi
Rosiñol, Laura
Tarantolo, Stefano
Terebelo, Howard
Yang, Shiyi
Wang, Jianping
Nnane, Ivo
Qi, Ming
Kosh, Michele
Delioukina, Maria
Goldschmidt, Hartmut
author_sort Moreau, Philippe
collection PubMed
description
format Online
Article
Text
id pubmed-9989580
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-99895802023-03-07 Daratumumab, carfilzomib, and dexamethasone in relapsed or refractory myeloma: final analysis of PLEIADES and EQUULEUS Moreau, Philippe Chari, Ajai Oriol, Albert Martinez-Lopez, Joaquin Haenel, Mathias Touzeau, Cyrille Ailawadhi, Sikander Besemer, Britta de la Rubia Comos, Javier Encinas, Cristina Mateos, Maria-Victoria Salwender, Hans Rodriguez-Otero, Paula Hulin, Cyrille Karlin, Lionel Sureda Balari, Anna Bargay, Joan Benboubker, Lotfi Rosiñol, Laura Tarantolo, Stefano Terebelo, Howard Yang, Shiyi Wang, Jianping Nnane, Ivo Qi, Ming Kosh, Michele Delioukina, Maria Goldschmidt, Hartmut Blood Cancer J Correspondence Nature Publishing Group UK 2023-03-07 /pmc/articles/PMC9989580/ /pubmed/36882409 http://dx.doi.org/10.1038/s41408-023-00805-x Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Correspondence
Moreau, Philippe
Chari, Ajai
Oriol, Albert
Martinez-Lopez, Joaquin
Haenel, Mathias
Touzeau, Cyrille
Ailawadhi, Sikander
Besemer, Britta
de la Rubia Comos, Javier
Encinas, Cristina
Mateos, Maria-Victoria
Salwender, Hans
Rodriguez-Otero, Paula
Hulin, Cyrille
Karlin, Lionel
Sureda Balari, Anna
Bargay, Joan
Benboubker, Lotfi
Rosiñol, Laura
Tarantolo, Stefano
Terebelo, Howard
Yang, Shiyi
Wang, Jianping
Nnane, Ivo
Qi, Ming
Kosh, Michele
Delioukina, Maria
Goldschmidt, Hartmut
Daratumumab, carfilzomib, and dexamethasone in relapsed or refractory myeloma: final analysis of PLEIADES and EQUULEUS
title Daratumumab, carfilzomib, and dexamethasone in relapsed or refractory myeloma: final analysis of PLEIADES and EQUULEUS
title_full Daratumumab, carfilzomib, and dexamethasone in relapsed or refractory myeloma: final analysis of PLEIADES and EQUULEUS
title_fullStr Daratumumab, carfilzomib, and dexamethasone in relapsed or refractory myeloma: final analysis of PLEIADES and EQUULEUS
title_full_unstemmed Daratumumab, carfilzomib, and dexamethasone in relapsed or refractory myeloma: final analysis of PLEIADES and EQUULEUS
title_short Daratumumab, carfilzomib, and dexamethasone in relapsed or refractory myeloma: final analysis of PLEIADES and EQUULEUS
title_sort daratumumab, carfilzomib, and dexamethasone in relapsed or refractory myeloma: final analysis of pleiades and equuleus
topic Correspondence
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9989580/
https://www.ncbi.nlm.nih.gov/pubmed/36882409
http://dx.doi.org/10.1038/s41408-023-00805-x
work_keys_str_mv AT moreauphilippe daratumumabcarfilzomibanddexamethasoneinrelapsedorrefractorymyelomafinalanalysisofpleiadesandequuleus
AT chariajai daratumumabcarfilzomibanddexamethasoneinrelapsedorrefractorymyelomafinalanalysisofpleiadesandequuleus
AT oriolalbert daratumumabcarfilzomibanddexamethasoneinrelapsedorrefractorymyelomafinalanalysisofpleiadesandequuleus
AT martinezlopezjoaquin daratumumabcarfilzomibanddexamethasoneinrelapsedorrefractorymyelomafinalanalysisofpleiadesandequuleus
AT haenelmathias daratumumabcarfilzomibanddexamethasoneinrelapsedorrefractorymyelomafinalanalysisofpleiadesandequuleus
AT touzeaucyrille daratumumabcarfilzomibanddexamethasoneinrelapsedorrefractorymyelomafinalanalysisofpleiadesandequuleus
AT ailawadhisikander daratumumabcarfilzomibanddexamethasoneinrelapsedorrefractorymyelomafinalanalysisofpleiadesandequuleus
AT besemerbritta daratumumabcarfilzomibanddexamethasoneinrelapsedorrefractorymyelomafinalanalysisofpleiadesandequuleus
AT delarubiacomosjavier daratumumabcarfilzomibanddexamethasoneinrelapsedorrefractorymyelomafinalanalysisofpleiadesandequuleus
AT encinascristina daratumumabcarfilzomibanddexamethasoneinrelapsedorrefractorymyelomafinalanalysisofpleiadesandequuleus
AT mateosmariavictoria daratumumabcarfilzomibanddexamethasoneinrelapsedorrefractorymyelomafinalanalysisofpleiadesandequuleus
AT salwenderhans daratumumabcarfilzomibanddexamethasoneinrelapsedorrefractorymyelomafinalanalysisofpleiadesandequuleus
AT rodriguezoteropaula daratumumabcarfilzomibanddexamethasoneinrelapsedorrefractorymyelomafinalanalysisofpleiadesandequuleus
AT hulincyrille daratumumabcarfilzomibanddexamethasoneinrelapsedorrefractorymyelomafinalanalysisofpleiadesandequuleus
AT karlinlionel daratumumabcarfilzomibanddexamethasoneinrelapsedorrefractorymyelomafinalanalysisofpleiadesandequuleus
AT suredabalarianna daratumumabcarfilzomibanddexamethasoneinrelapsedorrefractorymyelomafinalanalysisofpleiadesandequuleus
AT bargayjoan daratumumabcarfilzomibanddexamethasoneinrelapsedorrefractorymyelomafinalanalysisofpleiadesandequuleus
AT benboubkerlotfi daratumumabcarfilzomibanddexamethasoneinrelapsedorrefractorymyelomafinalanalysisofpleiadesandequuleus
AT rosinollaura daratumumabcarfilzomibanddexamethasoneinrelapsedorrefractorymyelomafinalanalysisofpleiadesandequuleus
AT tarantolostefano daratumumabcarfilzomibanddexamethasoneinrelapsedorrefractorymyelomafinalanalysisofpleiadesandequuleus
AT terebelohoward daratumumabcarfilzomibanddexamethasoneinrelapsedorrefractorymyelomafinalanalysisofpleiadesandequuleus
AT yangshiyi daratumumabcarfilzomibanddexamethasoneinrelapsedorrefractorymyelomafinalanalysisofpleiadesandequuleus
AT wangjianping daratumumabcarfilzomibanddexamethasoneinrelapsedorrefractorymyelomafinalanalysisofpleiadesandequuleus
AT nnaneivo daratumumabcarfilzomibanddexamethasoneinrelapsedorrefractorymyelomafinalanalysisofpleiadesandequuleus
AT qiming daratumumabcarfilzomibanddexamethasoneinrelapsedorrefractorymyelomafinalanalysisofpleiadesandequuleus
AT koshmichele daratumumabcarfilzomibanddexamethasoneinrelapsedorrefractorymyelomafinalanalysisofpleiadesandequuleus
AT delioukinamaria daratumumabcarfilzomibanddexamethasoneinrelapsedorrefractorymyelomafinalanalysisofpleiadesandequuleus
AT goldschmidthartmut daratumumabcarfilzomibanddexamethasoneinrelapsedorrefractorymyelomafinalanalysisofpleiadesandequuleus